Yandong Shen
0000-0002-1344-5143
19 papers found
Refreshing results…
Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL
Metastatic squamous cell carcinoma in chronic lymphocytic leukaemia in a haematology–dermatology multidisciplinary clinic
Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
Monoclonal B-cell Lymphocytosis – a review of diagnostic criteria, biology, natural history, and clinical management
COVID‐19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B‐lymphocytosis; humoural and cellular immunity
Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome
Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines
Adenylated proteins in mouse B16-F10 melanoma cells cluster in functional categories: a new paradigm for cellular regulation?
The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL
IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment
Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma
Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia
Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment
Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells
MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment
Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment
Modeling the chronic lymphocytic leukemia microenvironmentin vitro
Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer
Missing publications? Search for publications with a matching author name.